Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook

TEVA PHARMACEUTICAL INDUSTRIES LTD

2025-Q2 EPS reported $0.43 revenue$8,067,000,000

Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).
AUSTEDO global revs $498M (+19% LC), AJOVY $155M (+31% LC), UZEDY $54M (+120% YoY).
Raised 2025 revenue outlook: AUSTEDO $2,000-2,050M, AJOVY $630-640M, UZEDY $190-200M.
Non-GAAP operating margin 27.1% (vs 25.3% Q2 2024); adjusted EBITDA $1,233M (+6%).
Free cash flow $476M (+47% YoY); on track for $700M net savings by 2027 from Transformation programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.